Sigma Healthcare (ASX:SIG) YoY EBITDA Growth: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:SIG Sigma Healthcare Ltd ASX:SIG
47 GF Score
Price A$2.71
GF Value A$0.89
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sigma Healthcare YoY EBITDA Growth?

Sigma Healthcare ASX:SIG +0.74% 47 YoY EBITDA Growth is 0.00% as of Jun. 2026. GuruFocus rates ASX:SIG with a GF Score™ of 47/100 and a GF Value™ of A$0.89 (Significantly Overvalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Sigma Healthcare's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 0.00%.

Sigma Healthcare's EBITDA per Share for the six months ended in Jun. 2026 was A$0.05.

Sigma Healthcare YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Sigma Healthcare's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigma Healthcare YoY EBITDA Growth Chart

Sigma Healthcare Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.03 63.33 6.12 -32.69 182.86

Sigma Healthcare Semi-Annual Data
Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24 Jul24 Jan25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.63 -54.55 5.26 165.00 0.00
ASX:SIG
47GF Score
Sigma Healthcare Ltd ASX:SIG
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sigma Healthcare YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Sigma Healthcare's YoY EBITDA Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (A: Jun. 2026 )
=(EBITDA per Share (A: Jun. 2026 )-EBITDA per Share (A: Jan. 2025 ))/ | EBITDA per Share (A: Jan. 2025 ) |
=(0.099-0.035)/ | 0.035 |
=182.86 %

Sigma Healthcare's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jan. 2025 )) / | EBITDA per Share (Q: Jan. 2025 )) |
=(0.046-0.02)/ | 0.02 |
=130.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Sigma Healthcare (ASX:SIG) has a YoY EBITDA Growth of 0.00% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Sigma Healthcare and its competitors.
Is Sigma Healthcare's YoY EBITDA Growth too high?
Sigma Healthcare's current YoY EBITDA Growth is 0.00%. Overall, Sigma Healthcare has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sigma Healthcare's YoY EBITDA Growth compare to MCK and COR?
Sigma Healthcare's YoY EBITDA Growth of 0.00% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Distribution company?
A good YoY EBITDA Growth depends on the Medical Distribution industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Sigma Healthcare and its competitors. Sigma Healthcare's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigma Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sigma Healthcare (ASX:SIG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.89, compared to a current price of A$2.71 — trading 204.5% above its estimated fair value. The current YoY EBITDA Growth is 0.00%. Sigma Healthcare's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Sigma Healthcare (ASX:SIG), the current YoY EBITDA Growth is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sigma Healthcare (ASX:SIG) Overvalued in 2026?

Based on GuruFocus' analysis, Sigma Healthcare stock appears to be overvalued. The current stock price of A$2.71 is trading 204.5% above its estimated GF Value™ of A$0.89. GuruFocus considers Sigma Healthcare to be Significantly Overvalued.

Key valuation signals for ASX:SIG:

  • YoY EBITDA Growth: 0.00%
  • GF Value™: A$0.89 vs. price of A$2.71 (204.5% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the ASX:SIG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sigma Healthcare Business Description

Other Exchanges SIGGF:USA
Address 6 Albert Street, Preston, VIC, AUS, 3072
Sigma Healthcare is Australia's largest retail pharmacy franchisor, most notably owning the Chemist Warehouse brand, which it merged with in 2025. Sigma is also Australia's largest full-line wholesaler to franchised and independent pharmacies and distributes a broad range of pharmacy products, including prescription medicines, over-the-counter products, and front of store, or FOS, products, at low prices. The group also operates in New Zealand, Ireland, China, and Dubai, has a growing private label range, and offers third-party logistics services.
47GF Score

Get the complete analysis for ASX:SIG

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.71
Price
A$0.89
GF Value